2026 Michigan Medical Device Summit
Driving Innovation. Advancing Medtech. Changing Lives.
Wednesday, September 30, 2026
Washtenaw Community College, Ann Arbor
Where Michigan's Medical Device Ecosystem Connects, Innovates, and Grows
Join Michigan's premier Medical Device Summit to explore cutting-edge technologies, regulations, and industry insights. Network with top industry professionals, medtech innovators, researchers, manufacturing suppliers, investors, and government officials. Discover Michigan's thriving medtech ecosystem and its impact on innovation and economic growth.
REGISTER TODAY
WHY ATTEND?
Gain Strategic Insights – Learn about emerging technologies, regulatory updates, market trends, and industry best practices.
Build Valuable Connections – Network with medtech leaders, innovators, manufacturers, investors, and service providers.
Accelerate Innovation – Discover resources, partnerships, and opportunities that support product development and commercialization.
WHO SHOULD ATTEND?
Join us if you are:
- Industry executives and KOLs in the medtech sector
- Medtech product development experts
- Professionals in contract manufacturing, prototyping, or related services
- Medtech innovators
- Academic professionals engaged in medtech education
- Service specialists — regulatory, legal/IP, other providers
Be part of the conversation driving Michigan's medical technology cluster, and engage in intrastate partnering.
KEYNOTE SPEAKER
Michelle Tarver, MD, PhD
Director - Center for Devices and Radiological Health
U.S. Food & Drug Administration
Dr. Michelle Tarver is a visionary public health executive, board certified in ophthalmology with a doctorate in epidemiology, who serves as the Director for Devices and Radiological Health (CDRH). She has spent more than 15 years as a medical device regulator, driving strategic initiatives, conducting clinical research, and changing organizational culture. Dr. Tarver has held various leadership positions while at the FDA, including the Deputy Director of the Office of Strategic Partnerships and Technology Innovation, and the Program Director of Patient Science and Engagement. Over the course of her career, she has conducted laboratory-based epidemiological studies, clinical trials, and surveys to capture patient preferences, as well as developed registries and patient-reported outcome measures. Dr. Tarver has extensive policy experience in crafting regulations, guidances, and conducting premarket and postmarket reviews. She most recently served as the Deputy Center Director for Transformation, steering the development, implementation, and direction of CDRH's transformative projects and strategic initiatives. Under her leadership, CDRH has launched efforts to amplify the perspectives of people living with medical conditions, foster collaboration across the health care ecosystem, and stimulate creative evidence generation pathways.
Dr. Tarver received a B.S. in Biochemistry from Spelman College in Atlanta and completed the M.D./Ph.D. program at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health. As a dedicated clinician, she continues to care for people living with inflammatory eye conditions.
Conference Agenda Highlights
C-Suite Unplugged: The Future of Medtech: Navigating Transformation in an Era of AI, Regulation, and Global Competition
Medical technology is entering a period of unprecedented change. AI-enabled devices, evolving regulatory expectations, shifting supply chains, and mounting pressure to demonstrate value are reshaping the industry's future. This executive leadership panel explores the strategic decisions manufacturers are making today to remain competitive and drive innovation tomorrow.
Advancing Innovation, Ensuring Trust: A Conversation with FDA CDRH Director Dr. Michelle Tarver
As medical technology becomes increasingly sophisticated—from AI-enabled diagnostics and digital therapeutics to connected devices and advanced manufacturing—the role of regulatory leadership has never been more critical. Join Dr. Michelle Tarver, Director of the FDA's Center for Devices and Radiological Health (CDRH), for an engaging fireside chat exploring the agency's vision for fostering innovation while ensuring patient safety and public confidence. The discussion will examine emerging regulatory priorities, the future of AI oversight, opportunities to accelerate patient access to breakthrough technologies, and how FDA is partnering with industry to shape the next generation of medical devices.
Medtech at a Crossroads: Policy, Power, and the Fight for Innovation
From FDA reform and reimbursement pressures to global competition and supply chain security, policy decisions are increasingly determining which technologies reach patients - and which companies thrive. In this candid conversation, Greg Crist of AdvaMed explores the forces shaping the future of medtech and what industry leaders must do to ensure innovation remains a national priority.
MORE Information on additional sessions to be announced soon.
-
WHAT PREVIOUS ATTENDEES ARE SAYING
Manufacturer Perspective
“The Medical Device Summit was packed with actionable insights. The C-Suite Unplugged discussion was so informative, while the session on AI-Powered Healthcare gave a dynamic view of the future. It’s rare to find such concentrated, high-level content in one place. This event has become a must-attend for staying visible in Michigan’s medtech sector.”
-
WHAT PREVIOUS ATTENDEES ARE SAYING
Innovator/Startup Voice
“As a first-time founder navigating Michigan’s medtech landscape, this summit was a game-changer. I gained critical insights from regulatory experts, met funding partners, and had meaningful conversations with contract manufacturers and other startups. I walked away with real leads, ideas, and renewed confidence in our commercialization path.”
-
WHAT PREVIOUS ATTENDEES ARE SAYING
Contractor/Supplier Insights
“The summit provided an unparalleled opportunity to connect with OEMs and service partners, and prospective clients all in one place. The sessions on manufacturing automation and regulatory alignment were especially valuable for streamlining our upcoming product line. We’re already planning to bring more of our team next year.”
-
WHAT PREVIOUS ATTENDEES ARE SAYING
Regulatory Expert Take
“The summit hit all the hot-button regulatory topics. Between the in-depth sessions on biocompatibility, premarket submissions, and QMSR alignment with ISO 13485, and the capstone FDA Town Hall, there was no shortage of clarity or candid feedback. It was a goldmine for medtech professionals.”
